Sodium oxybate (Xyrem®), the sodium salt of γ- hydroxybutyric acid (GHB), is a first-line treatment of the symptoms induced by type 1 narcolepsy (NT1) and it is highly effective in improving sleep architecture, decreasing excessive daytime sleepiness and the frequency of cataplexy attacks. Using an ultra-high-performance liquid chromatography tandem mass spectrometry (UHPLC–MS/MS) validated method, GHB was determined together with its glucuronide (GHB-gluc), in plasma and cerebrospinal fluid (CSF) samples of NT1 patients under sodium oxybate treatment. To characterize the plasma pharmacokinetics of GHB, three subjects with NT1 were administered at time 0 and 4 h with 1.25, 1.5 and 3.55 g Xyrem®, respectively and had their blood samples collected at 7 time points throughout an 8-h session. CSF specimens, collected for orexin A measurement from the same three subjects 6 h after their second administration, were also tested. The results obtained suggested that GHB plasma values increased disproportionally with the rising doses, (Cmax0–4: 12.53, 32.95 and 69.62 μg/mL; Cmax4–8: 44.93, 75.03 and 111.93 μg/mL for total Xyrem® dose of 2.5, 3 and 7 g respectively) indicating non-linear dose-response. GHB-Gluc was present only in traces in all plasma samples from treated patients, not changing with increasing Xyrem® doses. GHB values of 5.62, 6.10 and 17.74 μg/mL for 2, 3 and 7 g Xyrem® were found in CSF with a significant difference from control values. GHB-Gluc was found in negligible concentrations with no differences to those of control individuals. In conclusion this simple and fast UHPLC–MS/MS method proved useful for pharmacokinetic studies and therapeutic drug monitoring of GHB in narcoleptic patients treated with sodium oxybate.
Ultra-high-performance liquid chromatography tandem mass spectrometry determination of GHB, GHB-glucuronide in plasma and cerebrospinal fluid of narcoleptic patients under sodium oxybate treatment / Tittarelli, Roberta; Pichini, Simona; Pedersen, Daniel S.; Pacifici, Roberta; Moresco, Monica; Pizza, Fabio; Busardò, Francesco Paolo; Plazzi, Giuseppe. - In: FORENSIC SCIENCE INTERNATIONAL. - ISSN 0379-0738. - 274(2017), pp. 70-74.
Data di pubblicazione: | 2017 |
Data di prima pubblicazione: | 25-gen-2017 |
Titolo: | Ultra-high-performance liquid chromatography tandem mass spectrometry determination of GHB, GHB-glucuronide in plasma and cerebrospinal fluid of narcoleptic patients under sodium oxybate treatment |
Autore/i: | Tittarelli, Roberta; Pichini, Simona; Pedersen, Daniel S.; Pacifici, Roberta; Moresco, Monica; Pizza, Fabio; Busardò, Francesco Paolo; Plazzi, Giuseppe |
Autore/i UNIMORE: | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.forsciint.2017.01.015 |
Rivista: | |
Volume: | 274 |
Pagina iniziale: | 70 |
Pagina finale: | 74 |
Codice identificativo ISI: | WOS:000401098800012 |
Codice identificativo Scopus: | 2-s2.0-85010900168 |
Codice identificativo Pubmed: | 28139340 |
Citazione: | Ultra-high-performance liquid chromatography tandem mass spectrometry determination of GHB, GHB-glucuronide in plasma and cerebrospinal fluid of narcoleptic patients under sodium oxybate treatment / Tittarelli, Roberta; Pichini, Simona; Pedersen, Daniel S.; Pacifici, Roberta; Moresco, Monica; Pizza, Fabio; Busardò, Francesco Paolo; Plazzi, Giuseppe. - In: FORENSIC SCIENCE INTERNATIONAL. - ISSN 0379-0738. - 274(2017), pp. 70-74. |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
1-s2.0-S0379073817300208-main.pdf | Versione dell'editore (versione pubblicata) | Administrator Richiedi una copia |

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris